– USA, CA – Enochian BioSciences, Inc. (NASDAQ: ENOB), a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Mark Dybul, M.D. who has served as Executive Vice-Chair of the Board since January 2019, has been named CEO.
“It is a great privilege to have one of the world’s preeminent public health experts assume the role of CEO of Enochian BioSciences,” said Board Chair, René Sindlev. “Mark’s deep expertise in science, combined with his long experience managing research programs and advising on strategy, brings key and difficult-to-find competencies to Enochian BioSciences. Under Mark’s leadership, we are excited to see the organization rapidly advance toward its goal of developing cures for HBV, HIV and potentially, to address inhaled pan-coronavirus and pan-influenza treatment and prevention.”
Gregg Alton, Board Director and former interim CEO, said, “I have known Mark since he worked closely with Tony Fauci, when I was General Counsel at Gilead Sciences. I watched him lead what was effectively a start-up in the U.S. Government, PEPFAR, and make it one of the most successful public health programs in history. Mark then went on to transform the Global Fund, a public-private partnership, introducing business models for purchasing, supply chain, and many others. He knows how to lead, develop strategy, maintain the teams’ focus and achieve success.”
About Dr. Mark Dybul
Dr. Mark Dybul is a globally recognized leader in pandemics and was a principal architect and ultimately the head of the U.S. President’s Emergency Plan for AIDS Relief, the largest international health initiative in history dedicated to a single disease, that achieved historic prevention, care and treatment goals on time and on budget. During his tenure, the program grew from approximately $500 million to $6.5 billion annually. Dr. Dybul went on to transform the Global Fund to Fight AIDS, Tuberculosis and Malaria and, during Dr. Dybul’s four-year tenure, both President Barack Obama and Prime Minister Justin Trudeau hosted funding rounds that raised $25 billion for the Global Fund.
Dr. Dybul has been deeply involved in the fight against COVID-19. He was the only American appointed to the 15-member Independent Panel for Pandemic Preparedness and Response, mandated by the World Health Assembly and co-chaired by former Liberian President Ellen Johnson Sirleaf and former New Zealand Prime Minister Helen Clark. Dr. Dybul also was a member of the High Level Scientific Advisory Group for the G20’s Global Health Summit focused on COVID-19.
Under the mentorship of Dr. Anthony Fauci, Dr. Dybul began his career in public health as a researcher at the National Institute of Allergy and Infectious Diseases, ultimately leading a section of Dr. Fauci’s lab and serving as the Assistant Director for Medical Affairs.
“As a long-time researcher, clinician, and leader of large global diseases programs, I am very honored to transition from my current role of Executive Vice-Chair to full-time CEO of Enochian BioSciences,” said Dr. Dybul. “Based in elegantly brilliant science, we have made significant progress in the past 18 months building a deep and wide pipeline with platforms that address major killers including cancer and infectious diseases. The recent acceleration of potential cures for Hepatitis B, HIV and potential inhaled pan-coronavirus, including the cause of COVID-19, and pan-influenza treatment and prevention — makes it an extremely exciting time to become the CEO of Enochian BioSciences.”
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology.
For more information : https://www.enochianbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.